1[1]Rothenberg ML.Efficacy and toxicity of irinotecan in patients with colorectal cancer[J].Semin Oncol，1998，25（5 suppl 11）:39.
2[2]Miya T， Fujikawa R， Fukushima J，et al.Bradycardia induced by irinotecan:a case report[J].Jpn J Clin Oncol，1998，28（11）:709.
3[3]Rivory LP，Chatelut E，Canal P，et al. Kinetics of the in vivo interconversion of the carboxylate and lactone for-ms of irinotecan（CPT-11）and of its metabolite SN-38 in patients[J].Cancer Res，1994，54(24):6 330.
4[4]Cunningham D，Pyrhonen S，James RD，et al.Random-ised trial of irinotecan plus supportive care versus sup-portive care alone after fluorouracil failure for patients with metastatic colorectal cancer[J].Lancet，1998，352（9138）:1 413.
5[5]Rougier P，Van Cutsem E，Bajetta E，et al.Randomised trial of irinotecan versus fluorouracil by continuous in-fusion after fluorouracil failure in patients with metas-tatic colorectal cancer[J].Lancet，1998，352（9138）:1 407.
6[6]Rowinsky EK，Baker SD，Burks K，et al.High-dose to-potecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer:a phaseⅡ and pharmacodynamic study[J].Ann Oncol，1998，9（2）:173.
7[7]Perez Soler R，Fossella FV，Glisson BS，et al.PhaseⅡstudy of topotecan in patients with advanced non-sm-all-cell lung cancer previously untreated with chemo-therapy[J].J Clin Oncol，1996，14（2）:503.
8[8]Gerrits CJ，Burris H，Schellens JH，et al.Oral topotecan given once or twice daily for ten days:a phase I pharmacology study in adult patients with solid tumors[J].Clin Cancer Res，1998，4（5）:1 153.
9[9]Perez Soler R，Glisson BS，Lee JS，et al.Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan[J].J Clin Oncol，1996，14（10）:2 785.
10[10]Langevin AM，Casto DT，Thomas PJ，et al.Phase I trial of 9-aminocamptothecin in children with refractory solid tumors:a pediatric oncology group study[J].J Clin Oncol，1998，16（7）:2 494.
